Aspira Pathlab & Diagnostics Ltd
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]
- Market Cap ₹ 94.5 Cr.
- Current Price ₹ 91.8
- High / Low ₹ 136 / 49.0
- Stock P/E 39.4
- Book Value ₹ 7.02
- Dividend Yield 0.00 %
- ROCE 17.0 %
- ROE 33.0 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 50.5 to 39.0 days.
- Promoter holding has increased by 28.2% over last quarter.
- Company's working capital requirements have reduced from 19.6 days to 14.1 days
Cons
- Stock is trading at 13.1 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 13.20 | 22.00 | 22.62 | |
| 14.38 | 18.49 | 19.15 | |
| Operating Profit | -1.18 | 3.51 | 3.47 |
| OPM % | -8.94% | 15.95% | 15.34% |
| 0.42 | 0.36 | 0.41 | |
| Interest | 0.37 | 0.35 | 0.00 |
| Depreciation | 1.54 | 1.49 | 1.49 |
| Profit before tax | -2.67 | 2.03 | 2.39 |
| Tax % | 0.00% | 0.00% | |
| -2.67 | 2.02 | 2.40 | |
| EPS in Rs | -2.59 | 1.96 | 2.33 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 177% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 40% |
| 1 Year: | 54% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 10.29 | 10.29 |
| Reserves | -5.08 | -3.06 |
| 7.71 | 8.13 | |
| 1.79 | 2.11 | |
| Total Liabilities | 14.71 | 17.47 |
| 6.79 | 6.53 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.08 |
| 7.92 | 10.86 | |
| Total Assets | 14.71 | 17.47 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1.05 | 1.83 | |
| 0.14 | 0.12 | |
| -0.95 | -0.99 | |
| Net Cash Flow | 0.24 | 0.95 |
| Free Cash Flow | 0.79 | 1.66 |
| CFO/OP | -89% | 52% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 61.94 | 38.99 |
| Inventory Days | 62.69 | 50.31 |
| Days Payable | 101.70 | 73.00 |
| Cash Conversion Cycle | 22.93 | 16.30 |
| Working Capital Days | 25.16 | 14.10 |
| ROCE % | 17.04% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Permanent Employees employees ・Standalone data |
|
|||||
| B2B Revenue Share % of revenue ・Standalone data |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication for the Financial Result as on 30 June 2026
-
Announcement under Regulation 30 (LODR)-Change in Management
- Board approved Q1 FY27 results; appointed Vaibhav Odhekar and redesignated Nikunj Mange as Managing Director.
-
Unaudited Standalone Financial Results For The Quarter Ended June 30, 2026
- Board approved Q1 FY27 results, appointed executive director, and re-designated Nikunj Mange as Managing Director.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th August 2026
- Board approved Q1 FY27 results, appointed new MD, and named additional executive director; fund-raising deferred.
-
Board Meeting Intimation for Approval Of Un-Audited Financial Result (Standalone) For The First Quarter Ended On June 30,2026 And To Transact Other Businesses
- Board meeting on Aug 12, 2026 to approve Q1 FY27 results and evaluate fund raising options.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1][2][3]
Aspira Pathlab & Diagnostics Ltd (APDL) provides pathology and radiology investigation services through diagnostic centers in Mumbai. Serving B2B and B2C markets, the company offers diagnostic solutions to individual patients, hospitals, healthcare providers, and businesses.